The University of Michigan will license an antigen to NanoBio Corporation for development of a nasal vaccine using NanoBio’s NanoStat technology for the prevention of urinary tract infections (UTIs). The antigen works by eliminating E. coli bacteria in the urinary tract. NanoBio’s press release cites statistics showing that more than half of all women suffer from UTIs every year and that 20% of those women experience recurrent infections.
Michigan professor Harry Mobley, chair of the university’s Department of Microbiology and Immunology explains that the deal will speed development: “We previously anticipated at least ten years of further development of the vaccine before reaching commercialization; however, partnering with NanoBio and using their NanoStat technology will significantly accelerate the development of this long-awaited vaccine.”
The Ann Arbor, Michigan company is developing a number of other mucosal vaccines to prevent diseases ranging from influenza to cancer, including smallpox, respiratory syncytial virus (RSV), and hepatitis B.
Read the NanoBio press release.
